SKB500 Combinations in Patients With Small Cell Lung Cancer
A phase 2 trial of KL-A167, Carboplatin, Etoposide in small-cell lung cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.
Overview
SKB500 Combinations in Patients With Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07296809 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 80 participants planned, started 2026-01-30 and due to reach its primary completion in 2028-12-31. Interventions recorded: SKB500 Powder for Injection, KL-A167 Injection, Carboplatin Injection, Etoposide Injection. Conditions listed: Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
Shares KL-A167, Sichuan Kelun-Biotech, Carboplatin, Small-cell lung cancer.
- TrialKL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Shares KL-A167, Sichuan Kelun-Biotech.
- TrialDAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment
Shares Etoposide, Carboplatin, Small-cell lung cancer.
- TrialStudy of AZD2811 + Durvalumab in ES-SCLC
Shares Etoposide, Carboplatin, Small-cell lung cancer.
- TrialPharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms
Shares Etoposide, Small-cell lung cancer.
- TrialA Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer
Shares Etoposide, Carboplatin, Small-cell lung cancer.
- TrialA Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-
Shares Sichuan Kelun-Biotech, Carboplatin, Small-cell lung cancer.
- TrialA Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
Shares Sichuan Kelun-Biotech, Carboplatin, Small-cell lung cancer.